Elekta Business Model Canvas

Integrations with EHRs, PACS, imaging and AI vendors enable end-to-end oncology workflows across Elekta’s installed base in over 120 countries, streamlining patient data flow from diagnosis to treatment.

Interoperability partnerships reduce friction and upgrade barriers, enabling smoother upgrades and faster clinical deployment.

Data collaborations enhance planning, QA and adaptive therapy, while secure APIs meet hospital IT and regulatory requirements.

Collaborations with cancer centers drive trials and evidence, shaping product roadmaps and adoption.

Suppliers co-engineer high-precision components; dual-sourcing lowers supply risk for ~4,000 employees in 120+ countries (2024).

Interoperability and data partners enable end-to-end workflows across >5,000 installed systems (2024).

Distributors, service partners and payer/regulatory engagement speed approvals, market access and uptime.

Design controls, verification and validation follow FDA 21 CFR 820.30, EU MDR (effective 26 May 2021) and IEC/ISO standards (IEC 62304, ISO 13485:2016) to ensure global compliance. Clinical studies and real‑world registries quantify efficacy and outcomes for Elekta systems across indications. Vigilance and post‑market surveillance meet MDR/FDA timelines (serious incident reporting typically within 15 days). Documentation supports global submissions.

R&D advances target submillimeter accuracy, supporting therapies indicated in ~50% of cancer patients (2024). Manufacturing adheres to ISO 13485 and AAPM TG‑142 (dose ±2%) with lean processes. Regulatory, clinical studies and software cycles follow FDA 21 CFR 820.30 and EU MDR; service expansion and remote monitoring in 2024 shortened repair times.

Physicists, engineers, clinicians and software developers at Elekta drive product innovation and clinical validation; in 2024 the group supported an installed base of over 5,000 systems across 120+ countries. Regulatory and quality experts enable compliant releases under MDR/IVDR and FDA pathways, while field engineers maintain >95% clinical uptime. Customer success teams focus on adoption, training and outcomes to protect service revenue and customer retention.

Elekta’s key resources combine 1,600+ patents (2024), proprietary software and maintenance contracts, a global installed base of >6,000 clinical systems across 120+ countries, field engineers sustaining >95% clinical uptime, calibrated production lines and qualified suppliers, CE mark and multiple FDA clearances, and KOL/reference center networks driving adoption.

Adaptive planning responds to anatomical and tumor changes in real time, enabling replanning between fractions and reducing geographic miss. Data-driven insights tailor dose and fractionation to biology and comorbidity profiles, supported by AI-enabled tools that can cut planning time by up to 80%. Patients receive more effective, individualized care with improved local control and reduced toxicity, reflecting 2024 trends toward personalized radiotherapy.

Sub-millimeter stereotactic precision with CBCT/MR guidance improves local control and reduces toxicity; Elekta reported SEK 14.6bn revenue in 2024 and 6,000+ installed systems. Adaptive, AI-enabled planning cuts planning time up to 80% and boosts throughput ~25%. Global service in 120+ countries raises uptime and predictable TCO (10–15-year lifecycle).

KOLs and designated centers of excellence co-develop features, with Elekta leveraging partnerships across 120+ countries (2024) to align clinical needs with product design. Joint clinical studies deliver peer‑reviewed outcomes evidence that supports sales and reimbursement discussions. Reference sites host demonstrations and peer visits, accelerating adoption through hands‑on experience. Continuous feedback loops from KOLs and sites directly shape product roadmaps and release priorities.

Elekta secures lifecycle revenue via 3–5 year service agreements with SLAs of 24–72 hours, supporting predictable multi‑year fees. Training and KOL programs across 120+ countries (2024) accelerate adoption and clinical validation. Digital portals handle ~150,000 service interactions (2024) and remote diagnostics reduce fix time by ~40%, with a 20,000‑member user community.

Participation in government tenders and GPO processes secures large-volume contracts for Elekta, with EU public procurement representing about 14% of GDP, underscoring scale. Competitive bids emphasize clinical outcomes and total cost of ownership to win tenders. Strict compliance with procurement rules and certifications is mandatory. Framework agreements streamline repeat orders and shorten procurement cycles.

Omnichannel reach: direct enterprise sales, 120+ country distributors, tenders and partner bundles drive adoption; webinars (53% attendance), conferences (30–40% of qualified leads) and case studies (+62% purchase intent) sustain long multi‑stakeholder cycles and post‑sale clinical implementation.

Radiosurgery and neurosurgery centers require sub-millimeter accuracy (<1 mm) for brain and functional cases, prioritize advanced imaging guidance and patient comfort, and operate on tight schedules that demand high system uptime (commonly targeted >99%). Adoption decisions are strongly driven by clinical evidence and peer-reviewed references, with institutions citing published outcomes and peer benchmarks as key procurement criteria in 2024.

Tertiary centers: high-volume reference sites needing integrated imaging/RT, training and rapid support; Elekta in 120+ countries (2024).

Community hospitals: cost‑constrained, seek reliability, ease‑of‑use and 3–5 year ROI; favor low‑maintenance scalable systems.

LMIC/public systems: prioritize affordability, durability and local training; 70% of cancer deaths in LMICs, 50–60% need radiotherapy (2024).

Elekta’s large installed base, roughly 6,000 clinical systems globally in 2024, drives sustained technician and spare-parts costs. Preventive maintenance and SLAs generate ongoing expense, with service revenue representing about 40% of group sales in 2024. Building and operating remote monitoring infrastructure adds capital and recurring IT costs. Warranty reserves are maintained to cover failure and recall risks, influencing cash provisions and margin.

Elekta’s 2024 cost base includes SEK 1.1bn R&D, heavy clinical-study and regulatory lifecycle costs. Precision components, logistics and installations drive COGS for an installed base >7,000 systems and ~6,000 clinical systems in 2024. Service, spares and SLAs—service revenue ~40% of group sales in 2024—plus warranty and IT add recurring OPEX.

Multi-year maintenance, parts and calibration packages form Elekta’s backbone for predictable recurring revenue, with service and software contributing roughly 40% of group sales in 2023 (annual report net sales ~16.6 billion SEK); tiered SLAs align to clinical needs and drive renewal rates above industry norms, stabilizing cash flows and improving visibility for multi-year forecasting.

Elekta earns large-ticket revenue from linacs, radiosurgery and brachytherapy with multi-year procurements and upgrade options; 2024 hardware-led sales supported group net sales of SEK 18.2 billion. Software, licenses and SaaS drove ~SEK 2.7 billion (15% of 2024 sales). Services, maintenance and consumables form recurring annuity streams; service/software contributed ~40% of group sales in 2023.